JP2024521920A - Ｍａｔ２ａ阻害剤及びｉｉ型ｐｒｍｔ阻害剤を含む併用療法 - Google Patents
Ｍａｔ２ａ阻害剤及びｉｉ型ｐｒｍｔ阻害剤を含む併用療法 Download PDFInfo
- Publication number
- JP2024521920A JP2024521920A JP2023574589A JP2023574589A JP2024521920A JP 2024521920 A JP2024521920 A JP 2024521920A JP 2023574589 A JP2023574589 A JP 2023574589A JP 2023574589 A JP2023574589 A JP 2023574589A JP 2024521920 A JP2024521920 A JP 2024521920A
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- compound
- pharma
- alkyl
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196008P | 2021-06-02 | 2021-06-02 | |
| US63/196,008 | 2021-06-02 | ||
| US202263362438P | 2022-04-04 | 2022-04-04 | |
| US63/362,438 | 2022-04-04 | ||
| US202263364360P | 2022-05-09 | 2022-05-09 | |
| US63/364,360 | 2022-05-09 | ||
| PCT/US2022/072693 WO2022256806A1 (en) | 2021-06-02 | 2022-06-01 | Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521920A true JP2024521920A (ja) | 2024-06-04 |
| JP2024521920A5 JP2024521920A5 (enExample) | 2025-06-11 |
Family
ID=84323602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574589A Pending JP2024521920A (ja) | 2021-06-02 | 2022-06-01 | Ｍａｔ２ａ阻害剤及びｉｉ型ｐｒｍｔ阻害剤を含む併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20240108626A1 (enExample) |
| EP (1) | EP4347569A4 (enExample) |
| JP (1) | JP2024521920A (enExample) |
| KR (1) | KR20240019172A (enExample) |
| AU (1) | AU2022287057A1 (enExample) |
| BR (1) | BR112023025360A2 (enExample) |
| CA (1) | CA3220160A1 (enExample) |
| CL (1) | CL2023003603A1 (enExample) |
| IL (1) | IL308853A (enExample) |
| MX (1) | MX2023014405A (enExample) |
| WO (1) | WO2022256806A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| US12503467B2 (en) | 2018-12-10 | 2025-12-23 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors |
| US12403137B2 (en) | 2019-10-28 | 2025-09-02 | Tango Therapeutics, Inc. | Compounds and methods of use |
| CN116568677B (zh) | 2020-07-31 | 2026-07-28 | 探戈医药股份有限公司 | 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物 |
| IL308853A (en) * | 2021-06-02 | 2024-01-01 | Ideaya Biosciences Inc | Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor |
| EP4458812A1 (en) * | 2021-12-27 | 2024-11-06 | Medshine Discovery Inc. | Pyrazole-1(2h)-phthalazinone compound and application thereof |
| EP4469447A1 (en) * | 2022-01-26 | 2024-12-04 | Tango Therapeutics, Inc. | Compounds and methods of use |
| CN118946549A (zh) * | 2022-04-22 | 2024-11-12 | 北京望实智慧科技有限公司 | 稠和哒嗪酮化合物作为prmt5抑制剂 |
| WO2023246873A1 (zh) * | 2022-06-23 | 2023-12-28 | 南京明德新药研发有限公司 | 氨基取代的杂芳基衍生物及其应用 |
| US20250376473A1 (en) * | 2022-07-01 | 2025-12-11 | Cytosinlab Therapeutics Co., Ltd. | Prmts inhibitor and use thereof |
| WO2024027703A1 (zh) * | 2022-08-02 | 2024-02-08 | 上海艾力斯医药科技股份有限公司 | 一种prmt5抑制剂、其制备方法及应用 |
| KR20250108633A (ko) * | 2022-10-25 | 2025-07-15 | 탱고 테라퓨틱스, 인크. | 결정질 형태, 약제학적 조성물 및 이의 사용 방법 |
| CN120265615A (zh) * | 2022-11-29 | 2025-07-04 | 正大天晴药业集团股份有限公司 | 含有二氢酞嗪的化合物 |
| WO2024118943A2 (en) * | 2022-11-30 | 2024-06-06 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor |
| TW202440126A (zh) * | 2022-11-30 | 2024-10-16 | 美商安進公司 | 利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療 |
| WO2024140923A1 (zh) * | 2022-12-30 | 2024-07-04 | 苏州浦合医药科技有限公司 | Prmt5-mta抑制剂 |
| CN118359607A (zh) * | 2023-01-17 | 2024-07-19 | 苏州浦合医药科技有限公司 | Prmt5-mta抑制剂 |
| AU2024252435A1 (en) * | 2023-04-13 | 2025-10-16 | Glaxosmithkline Intellectual Property (No.4) Limited | Combination therapy comprising a mat2a inhibitor and a topoisomerase inhibitor, a splicing inhibitor sulfonamide, or a kif18 inhibitor |
| JP2026515196A (ja) * | 2023-04-28 | 2026-05-14 | ファーマエンジン インコーポレーテッド | Ｍｔａ協同的ｐｒｍｔ５阻害剤 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN116283800B (zh) * | 2023-05-16 | 2023-07-18 | 英矽智能科技(上海)有限公司 | 氧代喹唑啉类化合物及其应用 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| IL326348A (en) * | 2023-08-08 | 2026-04-01 | Mirati Therapeutics Inc | Methods and compositions for treating malignant peripheral nerve sheath tumors |
| IL327063A (en) * | 2023-09-15 | 2026-05-01 | Ideaya Biosciences Inc | Methods for treating MAT2A-related diseases |
| CN121866246A (zh) * | 2023-09-20 | 2026-04-14 | 西藏海思科制药有限公司 | 一种含氰基的杂环化合物及其用途 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN121889382A (zh) * | 2023-11-08 | 2026-04-17 | 北京泰德制药股份有限公司 | Prmt5抑制剂及其制备方法 |
| CN122341615A (zh) * | 2023-12-01 | 2026-07-03 | 上海翰森生物医药科技有限公司 | 三并环类衍生物抑制剂、其制备方法和应用 |
| AU2025212321A1 (en) | 2024-01-26 | 2026-08-06 | Apeiron Therapeutics (Hong Kong) Ltd. | Pharmaceutical composition containing prmt5 inhibitor and mat2a inhibitor |
| WO2025166308A1 (en) * | 2024-01-31 | 2025-08-07 | Tango Therapeutics, Inc. | Crystalline forms, pharmaceutical compositions and methods of use thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217297A1 (en) * | 2024-04-09 | 2025-10-16 | Tango Therapeutics, Inc. | Prmt5 inhibitors for use in methods of treating mta-accumulating cancer |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025250569A1 (en) * | 2024-05-29 | 2025-12-04 | Amgen Inc. | Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017096165A1 (en) * | 2015-12-03 | 2017-06-08 | Agios Pharmaceuticals, Inc. | Mat2a inhibitors for treating mtap null cancer |
| US12503467B2 (en) * | 2018-12-10 | 2025-12-23 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors |
| CN120208880A (zh) * | 2019-09-12 | 2025-06-27 | 米拉蒂医疗股份有限公司 | Mta-协同prmt5抑制剂 |
| GEP20247638B (en) * | 2019-10-22 | 2024-07-10 | Lupin Ltd | Pharmaceutical combination of prmt5 inhibitors |
| US12403137B2 (en) * | 2019-10-28 | 2025-09-02 | Tango Therapeutics, Inc. | Compounds and methods of use |
| IL308853A (en) * | 2021-06-02 | 2024-01-01 | Ideaya Biosciences Inc | Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor |
-
2022
- 2022-06-01 IL IL308853A patent/IL308853A/en unknown
- 2022-06-01 AU AU2022287057A patent/AU2022287057A1/en active Pending
- 2022-06-01 JP JP2023574589A patent/JP2024521920A/ja active Pending
- 2022-06-01 WO PCT/US2022/072693 patent/WO2022256806A1/en not_active Ceased
- 2022-06-01 BR BR112023025360A patent/BR112023025360A2/pt unknown
- 2022-06-01 CA CA3220160A patent/CA3220160A1/en active Pending
- 2022-06-01 MX MX2023014405A patent/MX2023014405A/es unknown
- 2022-06-01 EP EP22817027.0A patent/EP4347569A4/en active Pending
- 2022-06-01 KR KR1020237045309A patent/KR20240019172A/ko active Pending
-
2023
- 2023-11-03 US US18/501,729 patent/US20240108626A1/en active Pending
- 2023-12-01 CL CL2023003603A patent/CL2023003603A1/es unknown
-
2024
- 2024-01-05 US US18/405,638 patent/US12115163B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4347569A4 (en) | 2025-03-26 |
| CL2023003603A1 (es) | 2024-07-12 |
| IL308853A (en) | 2024-01-01 |
| US20240108626A1 (en) | 2024-04-04 |
| CA3220160A1 (en) | 2022-12-08 |
| BR112023025360A2 (pt) | 2024-02-20 |
| AU2022287057A1 (en) | 2023-12-14 |
| US20240173326A1 (en) | 2024-05-30 |
| WO2022256806A1 (en) | 2022-12-08 |
| US12115163B2 (en) | 2024-10-15 |
| MX2023014405A (es) | 2024-04-30 |
| KR20240019172A (ko) | 2024-02-14 |
| EP4347569A1 (en) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20240019172A (ko) | Mat2a 억제제 및 유형 ii prmt 억제제를 포함하는 병용 요법 | |
| EP4351570A1 (en) | Combination therapy comprising a mat2a inhibitor and type i prmt inhibitor | |
| CN112689633B (zh) | 用于抑制Nav1.8的吡啶甲酰胺化合物 | |
| TWI694076B (zh) | 三唑并嘧啶化合物及其用途 | |
| US20200325130A1 (en) | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | |
| JP7114478B2 (ja) | 癌の治療のための配合剤 | |
| JP7236065B1 (ja) | トリアジン誘導体を含有する医薬組成物 | |
| CN109906224B (zh) | 三唑吡啶化合物及其应用 | |
| AU2025200238A1 (en) | KAT6 inhibitor methods and combinations for cancer treatment | |
| CN112010828B (zh) | Cdk7小分子抑制剂的化合物及其应用 | |
| US20250235426A1 (en) | Pharmaceutical Combination and Use Thereof | |
| US10738061B2 (en) | Inhibitors of RAD52 recombination protein and methods using same | |
| CN117715893A (zh) | 包含mat2a抑制剂和ii型prmt抑制剂的组合疗法 | |
| WO2020198067A1 (en) | Pkm2 modulators and methods for their use | |
| WO2020152462A1 (en) | Pyrrolobenzodiazepine derivatives as inhibitors of nf-kappa b for the treatment of proliferative diseases | |
| WO2023010102A1 (en) | Imidazo[1,2-b]pyridazinyl compounds and uses thereof | |
| JP2024544019A (ja) | 化合物 | |
| HK40035225A (en) | Pharmaceutical combination and use thereof | |
| HK40007742A (en) | Pharmaceutical combinations for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250602 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250602 |